Navigation Links
TIBCO Spotfire and INTEGROMICS Announce Genomics Data Analysis Solution to Radically Speed Drug Research and Development
Date:9/23/2008

Spotfire Platform Evolves with INTEGROMICS to Lead the Industry in Advancing Life Sciences Research, Discovery and Development

SOMERVILLE, Mass., Sept. 23 /PRNewswire-FirstCall/ -- TIBCO Software Inc. (Nasdaq: TIBX), together with INTEGROMICS, a provider of state-of-the-art software solutions for data management and data analysis in genomics, proteomics and drug discovery, today announced a solution for genomics research that provides researchers and scientists with a direct, interactive, visual approach to data analysis that rapidly reveals insights and unexpected relationships in genomics data.

Genomics technologies -- used by pharmaceutical R&D departments to understand disease biology and drug response in order to develop new and better drugs -- are now used across the entire drug development process to better understand disease biology, mechanisms of drug action, mechanisms of toxicity, and individuals and their response to a drug. Genomics-based biomarkers are dramatically impacting drug development by providing more precise diagnoses of disease states and drug response in individual patients. The software used to analyze and explore genomic data had not kept pace with the advancing genomics research. Spotfire and INTEGROMICS, however, joined forces to address the needs of modern genomics research in areas including biomarker research, translational medicine, and systems biology by introducing INTEGROMICS Biomarker Discovery for TIBCO Spotfire(R).

The scientific and workflow knowledge of INTEGROMICS, combined with the adaptability and ease of use of the TIBCO Spotfire platform, provide researchers with a powerful genomic data analysis environment. The new solution enables pharmaceutical, biotechnology, and academic research groups to quickly find and categorize complex patterns. With interactive analysis and high-impact visualization capabilities, researchers and scientists can examine the expression and annotation dimensions of their data and perform a variety of numerical analyses. Pharmaceutical companies can also use Spotfire(R) as a flexible analytics platform to allow them to combine and analyze new types of data in order to more quickly pursue their hypotheses and research strategies.

"Having developed microarray analytics for the last five years, we are confident that this combined solution will provide researchers with a powerful environment to accelerate discovery and provide accurate, up-to-date analytics from a single reliable source," said Alberto Pasqual, vice president of R & D, INTEGROMICS. "With this set of tools, life science researchers can ask and answer new questions and create an advanced problem solving environment."

"Genomics research typically involves measuring the activity of thousands of genes in many different treatments or conditions and combining that information with other information about the genes to uncover information about the biology of disease and treatment," said Christian Marcazzo, senior director of Life Science Analytics for TIBCO Spotfire. "This solution helps researchers and scientists address one of the industry's long standing challenges of creating knowledge from mass data by easily integrating multiple data sources and transforming data into an interactive decision-making asset."

About INTEGROMICS

INTEGROMICS, SL is a leading provider of IT solutions for life sciences (genomics and proteomics). It focuses on delivering products, services and training in two strategic areas: data management/integration and intelligent data analysis. The company has developed a network of collaborations both in industry and academia to provide complete technological solutions that will help our clients to achieve their goals. INTEGROMICS SL was founded in 2002 and is based in Granada, Spain, with offices in Madrid (Spain) and Philadelphia (USA). INTEGROMICS Inc. is a wholly owned subsidiary which was established in 2007. For more information: http://www.INTEGROMICS.com

About TIBCO

TIBCO Software Inc. is a leading provider of enterprise analytics software for next generation business intelligence. TIBCO Spotfire products offer a visual and interactive experience that helps professionals quickly discover new and actionable insights in information. Distinguished by its speed to insight and adaptability to specific business challenges, Spotfire rapidly reveals unseen threats and new opportunities, creating significant economic value. Spotfire customers include industry leaders among the Global 2000 that have deployed Spotfire analytics to gain an information advantage over their competitors. For more information, visit http://spotfire.tibco.com

TIBCO, TIBCO Software, TIBCO Spotfire, and Spotfire are trademarks or registered trademarks of TIBCO Software Inc. and/or its subsidiaries in the United States and/or other countries. All other product and company names and marks mentioned in this document are the property of their respective owners and are mentioned for identification purposes only.

The foregoing document includes a description of certain planned future availability of TIBCO product(s) or product functionality. Such description and projected timing is provided for informational purposes only and is subject to change without notice.

Contacts:

Jim Baptiste Amy Groden-Morrison

Davies Murphy Group, Inc. TIBCO Software Inc.

(781) 418-2438 (617) 702-1710

spotfire@daviesmurphy.com amorriso@tibco.com

http://www.daviesmurphy.com http://spotfire.tibco.com


'/>"/>
SOURCE TIBCO Software Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. TIBCO Spotfire and Integromics Partner on Development of Genomics Platform for Province of Andalusia
2. TIBCO Spotfire Puts the Spotlight on Screening at InfoTech for Pharma and Biotech
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
5. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
6. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
7. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
8. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... the Netherlands and LAGUNA HILLS, Calif. ... The Institute of Cancer Research, London ... use MMprofilerâ„¢ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients ... trial known as MUK nine . The University of ... trial, which is partly funded by Myeloma UK, and ICR ...
(Date:10/10/2017)... , ... October 10, 2017 , ... San Diego-based team ... its corporate rebranding initiative announced today. The bold new look is part of ... the company moves into a significant growth period. , It will also expand its ...
(Date:10/10/2017)... Oct. 10, 2017 International research firm Parks Associates ... speak at the TMA 2017 Annual Meeting , October 11 in ... the residential home security market and how smart safety and security products ... Parks Associates: Smart ... "The residential security market ...
(Date:10/9/2017)... , Oct. 9, 2017  BioTech Holdings announced ... by which its ProCell stem cell therapy prevents ... ischemia.  The Company, demonstrated that treatment with ProCell ... limbs saved as compared to standard bone marrow ... HGF resulted in reduction of therapeutic effect.  ...
Breaking Biology Technology:
(Date:4/11/2017)... , April 11, 2017 NXT-ID, ... security technology company, announces the appointment of independent Directors Mr. ... to its Board of Directors, furthering the company,s corporate ... ... NXT-ID, we look forward to their guidance and benefiting from ...
(Date:4/5/2017)... April 5, 2017 Today HYPR Corp. ... the server component of the HYPR platform is officially ... the end-to-end security architecture that empowers biometric authentication across ... has already secured over 15 million users across the ... of connected home product suites and physical access represent ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
Breaking Biology News(10 mins):